| Nov 21 |
Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting
|
| Nov 6 |
Bright Minds Biosciences Secures $35 Million Investment
|
| Nov 4 |
Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement
|
| Oct 30 |
Bright Minds Biosciences: BMB-101's Phase 2 Trials Could Unlock Epilepsy Market Potential
|
| Oct 23 |
Soaring $1-handle stocks leaping into IBKR’s most-active list may point to market froth
|
| Oct 21 |
Bright Minds and Firefly Neuroscience collaborate for EEG data in receptor agonist study
|
| Oct 21 |
Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data
|
| Oct 19 |
FDA is said to see “path forward” for ecstasy-based drug
|
| Oct 18 |
Bright Minds rebounds after $35M private placement
|
| Oct 18 |
Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement
|
